Join
Live feed
·
PRReleasevia Quantisnow
Nurix Therapeutics Inc. logo

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

ByQuantisnow·Wall Street's wire, on your screen.
NRIX· Nurix Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRIX (Nurix Therapeutics Inc.) and more on Quantisnow.